117 results about "Peptidase P" patented technology

Provided herein are compounds of formulae (I) - (IX), or pharmaceutically acceptable salts or deuterated forms thereof as defined herein. Also provided herein are pharmaceutical compositions comprising a compound of formula (I) - (IX) or pharmaceutically acceptable salt or deuterated form thereof, and methods of using a compound of formula (I) - (IX) or pharmaceutically acceptable salt or deuterated form thereof, e.g., in the treatment of a disease that is treatable by administration of a DPP1 inhibitor.

The invention provides a rehmannia fermented extract, a composition as well as a preparation method and application of the rehmannia fermented extract and the composition, and belongs to the technical field of biological medicines. According to the invention, raw dark green tea and rehmannia are fermented by using a single strain of eurotium cristatum to respectively obtain a raw dark green tea fermentation extract and a rehmannia fermentation extract. Experiments prove that the two extracts have a relatively good inhibition effect on dipeptidyl peptidase-4 when being independently used; furthermore, the two extracts are combined, and animal experiments prove that the composition has relatively good inhibitory activity on intestinal tract and excrement dipeptidyl peptidase-4 and also has a hypoglycemic effect.

Provided herein are compounds of formulae (I)-(IX), or pharmaceutically acceptable salts or deuterated forms thereof as defined herein. Also provided herein are pharmaceutical compositions comprising a compound of formula (I)-(IX) or pharmaceutically acceptable salt or deuterated form thereof, and methods of using a compound of formula (I)-(IX) or pharmaceutically acceptable salt or deuterated form thereof, e.g., in the treatment of a disease that is treatable by administration of a DPP1 inhibitor.

This invention discloses a quantitative detection kit for arginine peptidase, a qualitative detection kit for arginine peptidase, and their usage methods. The quantitative detection kit utilizes the specific substrate Nα-benzoyl-DL-arginine-4-ylbenzamide hydrochloride, which can be hydrolyzed by arginine peptidase to 4-ylbenzamide. 4-ylbenzamide has a maximum absorption peak at 405 nm, and the specific arginine peptidase activity can be rapidly detected at room temperature using spectrophotometry. The qualitative kit utilizes the specific substrate Nα-benzoyl-DL-arginine-β-naphthamide hydrochloride, which can be hydrolyzed by arginine peptidase to p-β-naphthamide. β-naphthamide combines with 4-(dimethylamino)cinnamaldehyde to form a compound that is visible to the naked eye as a pink color. The disulfide bond cleaving agent cuts the mucus disulfide bonds, exposing bacterial enzyme sites, and the synergistic effect of the enzyme activator enhances the reaction rate of arginine peptidase hydrolysis of the substrate, significantly improving the detection sensitivity of arginine peptidase in tongue coating samples.

Disclosed herein are vaccine constructs for producing a virus-like particle (VLP) capable of raising an immune response to an immunogen, and uses thereof, wherein the constructs comprise nucleic acid sequences encoding an immunogen and a polyprotein, wherein the polyprotein comprises two or more viral structural proteins, wherein at least two of the two or more viral structural proteins are separated by a signal peptidase sequence such that, when the polyprotein is expressed in a host cell, the signal peptidase sequence undergoes host cell peptidase-dependent cleavage to liberate the two or more viral structural proteins, thereby allowing the liberated structural proteins to self-assemble into a VLP carrying the immunogen.

Provided herein are compounds of Formulae (I), (II), (III), and (III-d). Also provided herein are methods of preparation of Formulae (I), (II), and (III-d). Further provided herein are methods of functionalizing or sequencing a peptide by reaction of compounds of Formula (III-d) with peptidases.

The invention discloses a polypeptide as well as preparation and application thereof, and belongs to the technical field of active peptides. According to the present invention, three active peptides are prepared from walnut meal protein, the amino acid sequences of the three polypeptides are respectively Leuu-Pro-Gln-Phe (LPQF), Leuu-Pro-Ser-Phe (LPSF) or Vla-Pro-Phe-Pro (VPFP), and the detection results show that the three polypeptides have inhibition activity on dipeptidyl peptidase-IV (DPP-IV), such that the three polypeptides can be used for preparing the blood sugar reducing drug.

The application belongs to the technical field of biotechnology, and particularly relates to application of albumin polypeptide gel beads in a product for treating or preventing sarcopenia. Egg white protein is used as raw material to extract protein, and albumin dipeptide-based peptidase-IV inhibitory peptide is prepared through a biological enzymolysis method. Bioinformatics analysis is used to screen out the inhibitory peptide TPYMFP, and the IC50 value of the inhibitory peptide TPYMFP for dipeptide-based peptidase-IV reaches 3.12 ± 0.49 mmol / L. Further, the optimal preparation conditions of sodium alginate SA and carboxymethyl chitosan CMCS-based gel beads CMCS / SA / TPYMFP are explored. When the SA concentration is 1.5% (w / v), the CMCS concentration is 0.5% (w / v), and the CaCl2 concentration is 1% (w / v), the polypeptide encapsulation rate is increased to 98.26% ± 0.25%. It is verified that the albumin polypeptide gel beads have good pH response characteristics, and efficient protection and intestinal target delivery of the sarcopenia inhibitory peptide are realized. The albumin polypeptide gel beads are applied to preparation of a product for treating or preventing sarcopenia, or in preparation of a related product for increasing muscle mass and strength.

The utility model relates to the technical field of peptide enzymolysis, in particular to a preparation device for enzymolysis extraction of small molecule peptides, which comprises an enzymolysis tank, a heat preservation sleeve is nested and connected on the outer surface of the enzymolysis tank, an auger shaft is rotatably connected in the enzymolysis tank, and a rotating shaft is fixedly connected at the upper end of the auger shaft in the enzymolysis tank. According to the utility model, the angle of the hinge rod is changed, and the fixed seat further drives the scraper to be close to the inner wall of the enzymolysis tank, so that the inner wall of the enzymolysis tank can be scraped through the scraper at the later stage of enzymolysis; the inner wall of the enzymolysis tank is prevented from being scraped all the time, the abrasion degree of the scraping plate is reduced, the positions of the first stirring blade and the second stirring blade are adjustable, raw materials and enzymes at different positions can be stirred conveniently, the stirring efficiency of the device is improved, and meanwhile after the outer surface of the scraping plate is abraded, the unabraded scraping plate can make contact with the inner wall of the enzymolysis tank.

The present invention relates to the dipeptidyl-peptidase I (DPPI or Cathepsin C) inhibitor of formula (I), which is useful in the prevention and / or treatment of bronchiectasis with certain underlying aetiologies, in the prevention and / or treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis or hidradenitis suppurativa using therapeutically efficacious dosages and to polymorphs of Compound (I) as well as to pharmaceutical compositions comprising Compound (I) and its polymorphs.

The invention relates to a pharmaceutical composition for reducing dentin hypersensitivity and a preparation method thereof, and belongs to the technical field of biological medicine, the pharmaceutical composition comprises chanterelle extract, rabdosia rubescens leaf extract, eggshell membrane protein peptide and bifidobacterium thermophile fermentation extract; the cantharellus cibarius extract is obtained by sequentially performing enzymolysis on cantharellus cibarius through compound enzyme, ginger protease and serratipeptidase and purifying enzymatic hydrolysate through an AB-8 macroporous resin column. The rabdosia rubescens leaf extract is obtained by ultrasonically extracting rabdosia rubescens leaves with an ethanol water solution and purifying an extracting solution with a composite filler adsorption column. The eggshell membrane protein peptide is obtained by carrying out enzymolysis on a shell membrane by virtue of ginger protease and ficin and purifying an enzymatic hydrolysate by virtue of a G-25 sephadex column. The fermentation extract of the bifidobacterium thermophilus is obtained by purifying fermentation liquor of the bifidobacterium thermophilus through an SP agarose gel FF column. All the components are compounded according to a specific ratio and have a synergistic effect, so that the dentin hypersensitivity can be relieved safely in a multi-effect manner.

Provided are fusion proteins that inactivate coronaviruses and uses thereof. The fusion proteins herein comprise an ACE2 peptidase domain comprising the amino acid sequence set forth in SEQ ID NO: 1 directly or via a linker connected to a coronavirus polypeptide therapeutic that targets the HR1 domain. The fusion proteins are broad-spectrum, highly potent, and can inactivate viruses at an early, free stage.

The application discloses a method and application of knocking down ubiquitin-specific peptidase 7 protein, and belongs to the field of biological medicine. The method for knocking down the USP7 protein comprises: specifically inhibiting the expression of USP7 in endothelial cells through gene intervention, and the gene intervention means comprises shRNA, siRNA or recombinant virus carrier-mediated USP7 expression down-regulation. Further provided is a USP7 knockdown reagent for preparing a drug for treating endothelial cell inflammation or a cardiovascular disease, in particular, the USP7 knockdown reagent is a USP7 knockdown virus carrier containing a Cdh5 promoter; the cardiovascular disease comprises heart failure, myocardial infarction or ischemic cardiomyopathy. The application specifically knocks down the expression of USP7 in endothelial cells through gene intervention, significantly improves the migration, tube formation capacity and reduces the apoptosis of the endothelial cells, repairs endothelial dysfunction, the USP7 knockdown virus carrier is used for preparing a drug for treating a cardiovascular disease, and has important clinical value.

This invention provides a fermented extract of Rehmannia glutinosa, a composition thereof, its preparation method, and its application, belonging to the field of biomedical technology. This invention obtains fermented extracts of black tea and Rehmannia glutinosa by fermenting black tea and Rehmannia glutinosa with a single strain of *Aspergillus cristatus*. Experiments have verified that both extracts, used alone, have good inhibitory effects on dipeptidyl peptidase-4. Further, combining the two extracts and verifying through animal experiments, shows that they have good inhibitory activity against dipeptidyl peptidase-4 in the intestine and feces, while also exhibiting a hypoglycemic effect.

Disclosed are a crystal of the compound (S)-N-((S)-1-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-1,4-oxazacycloheptane-2-carboxamide salt or a salt thereof, a preparation method therefor, and the uses thereof in pharmaceutical compositions and in medicine.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a ubiquitin specific peptidase 13 inhibitor in preparation of a medicine for treating chronic kidney diseases. According to the present invention, as the acknowledged ubiquitin specific peptidase 13 inhibitor, the results of the in vivo unilateral ureteral ligation animal experiment and the in vitro TGF-beta 1 induced cell experiment show that the Spautin-1 can be used as the ubiquitin specific peptidase 13 inhibitor, the Spautin-1 can be used for alleviating UUO induced renal interstitial fibrosis, alleviating in-vitro TGF-beta1 induced renal fibroblast activation and regulating and controlling the cell cycle process of the TGF-beta1 induced renal fibroblast. The Spautin-1 has the advantages that the UUO induced renal interstitial fibrosis can be alleviated, and the in-vitro TGF-beta1 induced renal fibroblast activation can be alleviated; therefore, the Spautin-1 can relieve the CKD-related diseases and can be used for preparing the medicine for treating the CKD and the related diseases. The invention provides a new medicine source for relieving and treating CKD, and has a good clinical application prospect.

Materials, methods, and systems for enhanced protease targeting. For example, methods for the targeting of kallikrein related peptidase 2 (KLK2) are provided.

The invention relates to the technical field of biological medicines, in particular to application of dipeptidyl peptidase 3 (DPP3) as a treatment target of septicopyemia-induced myocardial injury. The invention discloses a key action mechanism of dipeptidyl peptidase 3 (DPP3) in septicopyemia induced myocardial injury, and provides a novel septicopyemia cardiomyopathy intervention strategy taking DPP3 as a target spot based on the key action mechanism. A theoretical basis and an experimental basis are provided for developing early diagnosis tools and targeted therapy drugs for septicopyemia-induced cardiomyopathy, and remarkable clinical application value and significance are achieved.

The invention relates to the first hydrolase that specifically digests the archaeal type of a peptidoglycan (PG), the major component of the cell wall of methanogens, named Talosaminidase. The enzyme consists of a signal peptide, several bacterial IG domains, a glycosyl hydrolase, several archaeal PG binding domains and a peptidase domain. The double enzymatic activity for the glycosyl hydrolase and the peptidase maximizes the lysis of archaeal cells with a cell wall of the archaeal PG-type. Engineering the enzyme by removing the signal peptide and bacterial IG domains and keeping only the archaeal PG binding, glycosyl hydrolase and peptidase made the enzyme easier to express and purify, without negatively influencing the enzymatic activity. Therefore, engineered Talosaminidase can be used to regulate populations of archaeal methanogens in the industrial, agricultural and medical settings, and consequently methane production.

A method for treating cancer is provided. The method includes administering a combination of a Prolidase, also known as peptidase D (PEPD), in combination with a monoclonal antibody or antigen binding fragment thereof that binds with specificity to a clotting factor, such as Factor XII (FXII). A single dose of the monoclonal antibody is sufficient to enable a therapeutic effect of the PEPD.

The invention relates to new compounds of the general Formula (I), which are Dipeptidyl peptidase 9 (DPP9) enzyme inhibitors. The present invention further relates to specific compounds based on Formula (I) that binds to an E3 ligase and to DPP9 and induce proteolysis of DPP9. The invention also relates to specific DPP9 binding compounds comprising a probe moiety, according to formula (I). The present invention further relates to pharmaceutical compositions and their use thereof.

The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof),that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and / or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.

To find out a novel component having dipeptidyl peptidase-IV inhibitory activity, and provide a dipeptidyl peptidase-IV inhibitor, a hyperglycemia inhibitor and an anti-diabetic agent.SOLUTION: Tetrapeptide Ile-Pro-Ala-Gly and tripeptide Val-Ala-Tyr included in hydrolysate of almond-derived protein has dipeptidyl peptidase-IV inhibitory activity, and can be used as a dipeptidyl peptidase-IV inhibitor, a hyperglycemia inhibitor and an anti-diabetic agent.SELECTED DRAWING: None

The present invention relates to a novel adamantyl derivative or a pharmaceutically acceptable salt thereof, and a use thereof. The adamantyl derivative may be a dipeptidyl peptidase-4 (DPP4) inhibito

The invention discloses a pharmaceutical composition containing propranolol and a neutral endo-peptidase inhibitor, the pharmaceutical composition comprises propranolol and a neutral endo-peptidase inhibitor, and the propranolol and the neutral endo-peptidase inhibitor are combined and connected through a non-covalent bond. According to the invention, sacubitril and propranolol are combined into a dual-effect salt, so that the two active pharmaceutical ingredients are synchronously released, the drug effect is favorably improved, the synergistic effect is favorably generated in the treatment process, the side effect of propranolol is effectively reduced, and the clinical use values of sacubitril and propranolol are potentially improved; on the premise of ensuring the antihypertensive effect, the occurrence probability of side effects is effectively reduced, and the medication safety is improved.

The invention discloses a multifunctional bioactive peptide from highland barley and application of the multifunctional bioactive peptide. The bioactive peptide has an amino acid sequence as shown in SEQ ID NO: 1. The multifunctional bioactive peptide disclosed by the invention has the activity of inhibiting angiotensin converting enzyme, the activity of inhibiting dipeptidyl peptidase-4, the antioxidant activity and the anti-inflammatory activity, can be used for developing polypeptide medicines or functional foods with a disease treatment effect, and has a good application prospect.

In one aspect, the present disclosure relates to an immunogenic composition comprising conjugated O-polysaccharide molecules derived from E. coli lipopolysaccharides. In one embodiment, the O-polysaccharide molecules are conjugated to streptococcal C5a peptidase (SCP). In some embodiments, the O-polysaccharide molecules are conjugated to SCP using click chemistry.

To provide methods for treating CLN2 disease in pediatric subjects.SOLUTION: Provided herein are methods of treating neuronal ceroid lipofuscinosis (CLN2) disease in a subject less than 3 years old. In exemplary embodiments, the method comprises administering to the subject a formulation comprising recombinant human tripeptidyl peptidase-1 (rhTPP1) in an amount effective to treat the CLN2 disease in the subject. Also provided are methods of delaying the onset of CLN2 disease, or a symptom thereof, in a subject less than 3 years old. In exemplary embodiments, the method comprises administering to the subject a formulation comprising recombinant human tripeptidyl peptidase-1 (rhTPP1) in an amount effective to delay the onset of the CLN2 disease or symptom in the subject.SELECTED DRAWING: None

The present disclosure provides antibodies and polypeptides that specifically bind to kallikrein related peptidase 6 (KLK6). Also provided are compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

The invention discloses a method for enhancing the synthetic ability of yeast total protein and dipeptide tripeptide. Relates to the technical field of synthetic biology and metabolic engineering. According to the invention, the saccharomyces cerevisiae engineering strain with high protein synthesis capability and high endogenous dipeptide and tripeptide accumulation level is successfully constructed. The metabonomics analysis reveals the unique peptide fragment accumulation spectrum, especially the generation of a large amount of lysine-rich tripeptide at the C terminal, and proposes a potential mechanism of metabolic pathway'bottleneck 'caused by peptidase activity down-regulation in combination with proteome data. The recombinant strain has important application potential in the fields of single-cell protein, functional peptide products and the like.